BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23334269)

  • 21. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
    Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
    Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F
    Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Gastineau DA; Litzow MR; Fonseca R; Roy V; Rajkumar SV; Gertz MA
    Leukemia; 2007 Sep; 21(9):2035-42. PubMed ID: 17581613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of lenalidomide-based induction therapy on the mobilization of CD34
    Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
    Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.
    Cavallo F; Bringhen S; Milone G; Ben-Yehuda D; Nagler A; Calabrese E; Cascavilla N; Montefusco V; Lupo B; Liberati AM; Crippa C; Rossini F; Passera R; Patriarca F; Cafro AM; Omedè P; Carella AM; Peccatori J; Catalano L; Caravita T; Musto P; Petrucci MT; Boccadoro M; Palumbo A
    Leukemia; 2011 Oct; 25(10):1627-31. PubMed ID: 21637283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.
    Auner HW; Mazzarella L; Cook L; Szydlo R; Saltarelli F; Pavlu J; Bua M; Giles C; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2011 Mar; 46(3):364-7. PubMed ID: 20562926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
    Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
    Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.
    Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M
    Stem Cell Res Ther; 2015 Apr; 6(1):64. PubMed ID: 25889496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
    Morris CL; Siegel E; Barlogie B; Cottler-Fox M; Lin P; Fassas A; Zangari M; Anaissie E; Tricot G
    Br J Haematol; 2003 Feb; 120(3):413-23. PubMed ID: 12580955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF.
    Hacıoğlu S; Sarı I; Doğu MH; Keskin A
    Transfus Apher Sci; 2014 Feb; 50(1):71-4. PubMed ID: 24342458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
    Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.
    Chua CC; Lim HY; Chai KL; Ong J; Sim S; Wood C; Dickinson M; Campbell P; Hempton J; King H; Dowsing C; Bergin K; Muir S; Gibbs S; Grigg A
    Bone Marrow Transplant; 2018 Sep; 53(9):1116-1123. PubMed ID: 29523889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study.
    Kim JS; Yoon DH; Park S; Yoon SS; Cho SG; Min CK; Lee JJ; Yang DH; Kwak JY; Eom HS; Kim WS; Kim H; Do YR; Moon JH; Lee J; Suh C
    Ann Hematol; 2016 Mar; 95(4):603-11. PubMed ID: 26754633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma.
    Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    J Clin Apher; 2014 Dec; 29(6):305-10. PubMed ID: 24764270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.